ReviewDiabetes care2026
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026.
Review in Diabetes care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07687368 (Continuous Glucose Monitoring in Critically Ill Patients), which is not on this map. Cited by 141 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Continuous Glucose Monitoring in Critically Ill Patients: a Randomized Controlled Trial in the Intensive Care Units of Hospital Clínic of Barcelona (CGM-UCI23)
Who cites it
141 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Pooled it
- Disparities in GLP-1RA and SGLT2i Uptake: a Systematic Review and an Equity-First Framework for Cardiovascular-Kidney-Metabolic Care.Current cardiology reports · 2026Pooled it
- 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Journal of the American College of Cardiology · 2026Guideline
- MASLD and Atherosclerosis in Patients with Type 2 Diabetes Mellitus: A Systematic Review.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?International journal of molecular sciences · 2026Pooled it
- Prevalence and risk factors of hyperuricemia and gout in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Efficacy of Gegen Qinlian decoction plus metformin for type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2026 · on this mapPooled it
- A 52-Week Efficacy and Safety Study of Teneligliptin, as an Add-On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial (TERA305 Study).Diabetes, obesity & metabolism · 2026Trial
- A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI.Diabetes, obesity & metabolism · 2026Trial
- Efficacy and Safety of Intensifying Once-Weekly Insulin Icodec Treatment With Once-Weekly Semaglutide in Adults With Type 2 Diabetes: A Single-Arm, Open-Label, Treat-to-Target, Phase 3b Trial (ONWARDS 8).Diabetes, obesity & metabolism · 2026Trial
- Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials.Diabetes, obesity & metabolism · 2026Trial
- Inpatient safety, effectiveness of SGLT2 inhibitors and GLP-1 RAs in type 2 diabetes: ENDOCARE, a pragmatic prospective cohort study.Cardiovascular diabetology · 2026Trial
- Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes.Journal of diabetes and metabolic disorders · 2026Article
- Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis in an adolescent with type 2 diabetes.JCEM case reports · 2026Article
- Use of Glucose-Lowering Drugs for Type 2 Diabetes Among Danish Care Home Residents.Diabetes, obesity & metabolism · 2026Article
- Incretin-based injectable strategies versus intensified insulin for treatment intensification and simplification in type 2 diabetes: a systematic review and meta-analysis.Journal of diabetes and metabolic disorders · 2026Article
- Effects of chiglitazar on glycemic, lipid, and hepatic outcomes: A systematic review and meta-analysis.Journal of diabetes and metabolic disorders · 2026Review
- Clinical pharmacology of antidiabetic drugs: an update.European journal of clinical pharmacology · 2026Review
- Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters.Endocrine journal · 2026Article
- Sodium-glucose cotransporter 2 inhibitors in diabetic kidney disease.Kidney research and clinical practice · 2026Article
81 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee for Diabetes, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.